Document Detail

Open, single-blind, double-blind: which peer review process do you prefer?
Jump to Full Text
MedLine Citation:
PMID:  25266119     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BMC Pharmacology and Toxicology was created from the merger of two journals within the BMC series published by BioMed Central: BMC Pharmacology and BMC Clinical Pharmacology. BMC Pharmacology operated anonymous peer review whereas BMC Clinical Pharmacology operated a fully open peer review policy where the identity of the reviewers was known to the editors, authors and readers. The merged journal also adopted a fully open peer review policy. Two years on we discuss the views and experiences of our Editorial Board Members towards open peer review on this biomedical journal.
Authors:
Elizabeth C Moylan; Simon Harold; Ciaran O Neill; Maria K Kowalczuk
Related Documents :
1553589 - Epidural lipomatosis in steroid-treated patients.
11148079 - Subependymoma of the spinal cord: case report and review of the literature.
3559609 - Focal cervical poliopathy causing juvenile muscular atrophy of distal upper extremity: ...
11380369 - Sonographic diagnosis of diastematomyelia in utero: a case report and literature review.
16357499 - Spinal intradural-intramedullary cavernous malformation. case report and literature rev...
17114859 - Cases of glioblastoma multiforme metastasizing to spinal cord.
6880559 - Pleural effusion with dyspnea as the presenting symptom in chronic pancreatitis. a case...
7924519 - Atrial-esophageal fistula shown by transthoracic echocardiogram.
15138939 - Primary appendiceal melanoma: fiction or reality?
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-9-30
Journal Detail:
Title:  BMC pharmacology & toxicology     Volume:  15     ISSN:  2050-6511     ISO Abbreviation:  BMC Pharmacol Toxicol     Publication Date:  2014 Sep 
Date Detail:
Created Date:  2014-9-30     Completed Date:  -     Revised Date:  2014-10-1    
Medline Journal Info:
Nlm Unique ID:  101590449     Medline TA:  BMC Pharmacol Toxicol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  55     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): BMC Pharmacol Toxicol
Journal ID (iso-abbrev): BMC Pharmacol Toxicol
ISSN: 2050-6511
Publisher: BioMed Central
Article Information
Download PDF
Copyright © 2014 Moylan et al.; licensee BioMed Central Ltd.
open-access:
Received Day: 4 Month: 9 Year: 2014
Accepted Day: 10 Month: 9 Year: 2014
collection publication date: Year: 2014
Electronic publication date: Day: 30 Month: 9 Year: 2014
Volume: 15First Page: 55 Last Page: 55
PubMed Id: 25266119
ID: 4191873
Publisher Id: 2050-6511-15-55
DOI: 10.1186/2050-6511-15-55

Open, single-blind, double-blind: which peer review process do you prefer?
Elizabeth C Moylan1 Email: elizabeth.moylan@biomedcentral.com
Simon Harold2 Email: simon.harold@nature.com
Ciaran O’Neill1 Email: ciaran.oneill@biomedcentral.com
Maria K Kowalczuk1 Email: maria.kowalczuk@biomedcentral.com
1BioMed Central Ltd, 236 Gray’s Inn Road, London WC1X 8HL, UK
2Present Address: Nature Communications, The Macmillan Campus, 4 Crinan Street, London N1 9XW, UK

The story so far

The BMC series of journals was established in 2000 by BioMed Central to provide open access to research published across a range of disciplines in biology and medicine [1]. Over the years, new journals have been launched to fulfil a particular research need (BMC Veterinary Research 2005, BMC Systems Biology 2007 and BMC Psychology 2013 are among such examples). All the biology journals within the BMC series operate traditional anonymous peer review, where the authors do not know who the reviewers are. However, the medical journals were established with open peer review, where the identity of the reviewers is known to all parties – editors, authors and readers [2].

Two years ago the pharmacology titles in the BMC series, BMC Pharmacology (a biology journal) and BMC Clinical Pharmacology (a medical journal), joined forces under the new title BMC Pharmacology and Toxicology[3]. The combined journal retained the full scopes of the original titles while also expanding to explicitly include the field of toxicology. Many of the original Editorial Board Members remained associated with the journal, and new academics and clinicians also joined.

In merging a biology journal operating anonymous peer review with a medical journal operating open peer review, we debated what the peer review process should be on BMC Pharmacology and Toxicology. In the end, the journal naturally retained the open peer review policy previously adopted by BMC Clinical Pharmacology – in keeping with all the other medical titles in the BMC series. BMC Cancer, another journal in the BMC series with biology and medicine disciplines, also operates open peer review.

Under open peer review, authors know who reviewed their manuscript (reviewer reports are signed) and, if the manuscript is published, the reader will also see the reviewers’ comments and the authors’ response. These comments are published as part of the ‘pre-publication history’ accompanying the published article, which also contains all versions of the manuscript and (where relevant) editors’ comments. By making the peer review process completely transparent we aim to reduce the competing interests that can occur especially for a journal which frequently publishes research sponsored by pharmaceutical companies [4]. See this recent article [5] for an example of a pre-publication history [6].

While many have recently discussed the benefits of open peer review including transparency, accountability and giving credit to reviewers [7-11], there are challenges too. Potential reviewers may be more likely to decline to review [12] and some (junior) reviewers may be reluctant to sign a critical report [13,14]. There are field-specific differences too. Medical disciplines with the particular need to be transparent about treatments for patients and competing interests appear to be more willing to embrace open peer review than the biological sciences. However, within biology there are differences between research fields, too: for example, the bioinformatics and genomics communities seem to accept open peer review more readily than traditional subjects such as immunology and physiology [15]. Perhaps this reflects their familiarity with features of open-source software and social-networking technologies [16].

At the time of the merger of BMC Pharmacology and BMC Clinical Pharmacology, we said that we would report on our findings of open peer review with the resulting biomedical journal. So, two years down the line, how have things fared with BMC Pharmacology and Toxicology?


Our survey says…

The Editorial Board Members on BMC Pharmacology & Toxicology represent a broad demographic from which to solicit views on open peer review given their variety of expertise in biology and clinical disciplines. Therefore, we surveyed the current members of the Editorial Board with eight questions (see Table 1). These covered their particular expertise and whether they preferred one system of peer review over another as an author, reviewer, or handling editor. Table 2 gives a summary of the main systems of peer review that were included for the purpose of this survey. We also asked whether our Editors read the pre-publication histories which accompany published articles. Finally, any other comments on open peer review were welcomed.

Of the 83 Editorial Board Members approached we received 37 replies (a response rate of 45%). Half the replies were from medics (of whom a third were practicing clinicians) and half were from non-medical fields including biology, chemistry and pharmaceutical sciences. The anonymised answers are provided in Additional file 1.It is clear that the Editorial Board Members who did respond were consistent in that, regardless of their potential role as ‘author’, ‘reviewer’ or ‘editor’, they prefer the same system of peer review. It was not the case that Editorial Board Members preferred one type of peer review system in their role as editor, and another in their role as reviewer (for example). Somewhat surprisingly, the majority of Editorial Board Members preferred double-blind peer review over open peer review (see Figure 1). Among the reasons put forward in support of double-blind peer review was the fact that this was perceived to be the most objective system and thus minimized bias. However, Editorial Board Members appreciated that it may not be very effective in practice as it may be possible to infer from the methods used, or reference list, who the authors are.

Although some Editorial Board Members recognised the value of open peer review, commenting that it is more egalitarian, increasing accountability and transparency, it was felt that open peer reviews may be more difficult for early career researchers to provide - as has been noted again recently [17]. Our survey suggested that the more early career researchers preferred double-blind peer review while the more senior Editorial Board Members preferred single-blind or double-blind models (Figure 2).

In their role as authors, approximately half of the Editorial Board had published in an open peer review journal (see Figure 3). The majority found that the reports they received during an open peer review process were equally useful to those received under anonymous peer review. However, in previous research [18] we have found that the quality of reports received was slightly higher under open peer review than anonymous peer review. Reviewers under an open peer review system provided more feedback on the methods, more constructive comments on the content and substantiated their feedback better with explicit evidence [18].

Finally, approximately half of the respondents of this survey read the pre-publication history which accompanies open peer reviewed articles in the BMC series, including BMC Pharmacology and Toxicology (see Figure 4). The pre-publication history contains all versions of the manuscript, named reviewer reports, author responses and (where relevant) editors’ comments. Of those Editorial Board Members who reported that they did not look at the pre-publication history, many simply had no time or inclination to do so or wanted to judge an article on its own merits. Some simply did not appreciate this information was provided. However, of those that did look, many did so in order to determine the scientific and ethical credentials of the reviewers and for further insights into peer review.

The survey has provided a sample of the views and experiences of academics and clinicians with respect to peer review on a biomedical journal, and as a result we appreciate there are improvements which can be made. However, this small survey has some limitations too. The low response rate limits the generalizability of the findings; we were not able to draw any specific conclusions reflecting (for example) the attitudes of particular groups based on gender/subject background/seniority towards different systems of peer review.


What next?

So two years into the open peer review experiment on BMC Pharmacology and Toxicology, will we continue to operate an open peer review system? Put simply: yes.

Among the Editorial Board Members who responded to our survey, there appears to be an overall preference for a peer review system that is double-blind (where authors and reviewers are not revealed to each other). Other much larger surveys have also come to similar conclusions [17,19,20]. However, it is unclear if this is a genuine feeling among researchers or rather ‘wishful thinking’ that double-blind peer review intuitively seems the fairest approach [21]. Certainly not many biology and medical journals operate double-blind peer review and from a pragmatic view point it is difficult to prevent reviewers from guessing who the authors are.

We will continue with open peer review at BMC Pharmacology and Toxicology because of the ethical grounds for doing so [2] and because the potential benefits outweigh the negatives [22,23]. Open peer review provides a fully transparent pre-publication history, and the reading public can see who reviewed the manuscript and what was said. Having access to peer reviews also provides valuable information for training purposes [24,25] and allows further research into the benefits of peer review [26]. And by making peer review completely open and reviewers (and editors) accountable, we aim to reduce the competing interests that can occur. But perhaps more relevant, in this era of ‘predatory publishers’ [27] and ‘sting’ operations [28] open peer review ensures that the decision-making process is fully transparent for all to see.

From the feedback we receive more generally from authors on our open peer review journals in the BMC series, many value the helpfulness, quality and detail of the reports. But given the responses received from our Editorial Board Members we need to make more of the fact that the pre-publication history is provided for readers and what it contains.

If you have any further feedback on the open peer review policy operated by BMC Pharmacology and Toxicology we’d certainly welcome your comments.


Competing interests

ECM, CON and MK are employed by BioMed Central. SH is employed by Nature Publishing Group.


Authors’ contributions

SH and CON designed the survey. EM and MK collated the data. MK analysed the data. EM wrote the first draft and revised the text. All authors contributed to the writing of the manuscript and approved the final version.


Authors’ information

ECM is the Biology Editor at BioMed Central. SH is an Associate Editor at Nature Communications. CON is Associate Publisher at BioMed Central and Editor of Biome. MK is the Deputy Biology Editor at BioMed Central.


Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/2050-6511/15/55/prepub


Supplementary Material Additional file 1

Anonymised survey responses from the Editorial Board.


Click here for additional data file (2050-6511-15-55-S1.xlsx)


Acknowledgements

Our thanks to Paul Lambert for contacting the Editorial Board; Caroline Black, Scott Edmunds, Christopher Morrey and Jigisha Patel for their comments on the text; and the Editorial Board Members of BMC Pharmacology and Toxicology for their participation in this survey.


References
BioMed CentralBMC series journals http://www.biomedcentral.com/authors/bmcseries.
Godlee F,Making reviewers visible: openness, accountability, and creditJAMAYear: 2002287212762276510.1001/jama.287.21.276212038905
Moylan EC,Morrey C,Appleford-Cook JM,Only connect: the merger of BMC Pharmacology and BMC Clinical PharmacologyBMC Pharmacol ToxicolYear: 201213110.1186/2050-6511-13-122946996
DeAngelis CD,Conflict of interest and the public trustJAMAYear: 20002842237223810.1001/jama.284.17.223711056597
Heard K,Green JL,Anderson V,Bucher-Bartelson B,Dart RC,A randomized, placebo-controlled trial to determine the course of aminotransferase elevation during prolonged acetaminophen administrationBMC Pharmacol ToxicolYear: 2014153910.1186/2050-6511-15-3925047090
Pre-publication history http://www.biomedcentral.com/2050-6511/15/39/prepub.
Edmunds EC,Peering into peer-review at GigaScienceGiga SciYear: 20132110.1186/2047-217X-2-1
Kriegeskorte N,Open evaluation: a vision for entirely transparent post-publication peer review and rating for scienceFront Comput NeurosciYear: 201267923087639
Lee CJ,Sugimoto CR,Zhang G,Cronin B,Bias in peer reviewJ Assoc Inf Sci TechnolYear: 201364210.1002/asi.22784
Amsen E,What is open peer review? http://blog.f1000research.com/2014/05/21/what-is-open-peer-review/.
Harriman S,A case for open peer review for clinical trials http://blogs.biomedcentral.com/bmcblog/2014/06/04/a-case-for-open-peer-review-for-clinical-trials/.
van Rooyen S,Godlee F,Evans S,Black N,Smith R,Effect of open peer review on quality of reviews and on reviewers' recommendations: A randomised trialBMJYear: 1999318232710.1136/bmj.318.7175.239872878
Khan K,Is open peer review the fairest system?No BMJYear: 2010341c642510.1136/bmj.c6425
McGlynn T,Why I prefer anonymous reviews http://smallpondscience.com/2014/03/26/why-i-prefer-anonymous-peer-reviews/.
Koonin EV,Landweber LF,Lipman DJ,Biology Direct: celebrating 7 years of open, published peer reviewBiol DirectYear: 201381110.1186/1745-6150-8-1123631729
Ghosh SS,Kliein A,Avants B,Millman KJ,Learning from open source software projects to improve scientific reviewFront Comput NeurosciYear: 201261822529798
Mulligan A,Hall L,Raphael E,Peer review in a changing world: An international study measuring the attitudes of researchersJ Assoc Info Sci TechnolYear: 201264132161
Kowalczuk MK,Dudbridge F,Nanda S,Harriman SL,Moylan EC,A comparison of the quality of reviewer reports from author-suggested reviewers and editor-suggested reviewers in journals operating on open or closed peer review modelsF1000PostersYear: 201341252 poster.
Ho RC,Mak KK,Tao R,Lu Y,Day JR,Pan F,Views on the peer review system of biomedical journals: an online survey of academics from high-ranking universitiesBMC Med Res MethodolYear: 2013137410.1186/1471-2288-13-7423758823
Ware M,Monkman M,Peer review in scholarly journals: Perspective of the scholarly community — an international studyYear: 2008Publishing Research Consortium
Nature EditorialWorking double-blindNatureYear: 2008451605606
Smith R,Opening up BMJ peer reviewBMJYear: 199931871754510.1136/bmj.318.7175.49872861
van Rooyen S,Delamothe T,Evans SJ,Effect on peer review of telling reviewers that their signed reviews might be posted on the web: randomised controlled trialBMJYear: 2010341c572910.1136/bmj.c572921081600
Russell F,Should there be training for peer reviewers? http://blogs.biomedcentral.com/bmcblog/2014/05/16/should-there-be-training-for-peer-reviewers/.
Patel J,Why training and specialization is needed for peer review: a case study of peer review for randomized controlled trialsBMC MedYear: 20141212810.1186/s12916-014-0128-z25285376
Hopewell S,Collins GS,Boutron I,Yu LM,Cook J,Shanyinde M,Wharton R,Shamseer L,Altman DG,Impact of peer review on reports of randomised trials published in open peer review journals: retrospective before and after studyBMJYear: 2014349g414510.1136/bmj.g414524986891
Beall J,Predatory publishers are corrupting open accessNatureYear: 201248917910.1038/489179a22972258
Bohannon J,Who's Afraid of Peer Review?ScienceYear: 2013342606510.1126/science.342.6154.6024092725

Figures

[Figure ID: F1]
Figure 1 

Piechart of the responses received from the Editorial Board to the question: ‘As a reviewer which peer review system do you prefer?’



[Figure ID: F2]
Figure 2 

Diagram of the preferences for a given peer review model classified by years of academic experience.



[Figure ID: F3]
Figure 3 

Piechart of the responses received from the Editorial Board to the question: ‘As an author, have you published in an open peer review journal?’



[Figure ID: F4]
Figure 4 

Piechart of the responses received from the Editorial Board to the question: ‘As a reader do you look at the pre-publication histories on BMC Pharmacology and Toxicology (or any of the open peer review journals in the BMC series)?’



Tables
[TableWrap ID: T1] Table 1 

Survey questions to the BMC Pharmacology & Toxicology Editorial Board


Number Questions
1.
Is your area of expertise in medicine or biology?
If medicine, are you a clinical academic or full time academic?
2.
How many years have you been working as an academic?
3.
Choose one that best describes you:
I was on the original board of BMC Clinical Pharmacology
I was on the original board of BMC Pharmacology
I joined the editorial board of BMC Pharmacology and Toxicology within the last 2 years.
4.
As an author, have you published in an open peer review journal? (meaning that the reviewers’ identity was revealed to you as an author)
4a (if yes) Do you think reports were less/equally/more useful to you than those from a closed peer review journal? If you have never published in a closed peer review journal please go to the next question.
4b (if no) Would you consider publishing in an open peer review journal? (if no, why?)
5.
As a reviewer which peer review system do you prefer, and why?
5a Open (authors and reading public know reviewers’ identity)
5b single-blind (i.e. reviewers know authors’ identity but not vice versa)
5c double-blind (i.e. authors and reviewers do not know each other’s identity)
6.
As a handling editor do you prefer a different (from your answer to question 5) model of peer review?
6a (If yes), which model do you prefer and why do you have a different preference as an editor compared to as a reviewer?
7.
As a reader do you look at the pre-publication histories on BMC Pharmacology and Toxicology (or any of the open peer review journals in the BMC series)?
7a If no, why not?
7b If yes, what is your main reason for looking at the pre-publication history?
8. Do you have any further comments on open peer review?

[TableWrap ID: T2] Table 2 

Definitions of open, single-blind and double-blind peer review as operated by BioMed Central


Open peer review
Editors, authors and reviewers know each other’s identity. If the manuscript is published, the reviewer reports, any editors’ comments, authors’ response and all versions of the manuscript are available via an accompanying ‘pre-publication history’.
Single-blind peer review
Reviewers know authors’ identity but not vice versa.
Double-blind peer review Authors and reviewers do not know each other’s identity


Article Categories:
  • Editorial


Previous Document:  The prevalence and socio-demographic correlates of depressive symptoms among Cypriot university stud...
Next Document:  Inferring phylogenies of evolving sequences without multiple sequence alignment.